Skip to content

Drug interactions

Aprepitant + Tazemetostat

Severity: Major

Aprepitant and Tazemetostat: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Tazemetostat is a CYP3A4 substrate, and aprepitant can increase its concentrations. This may increase the risk of its adverse effects.

What this interaction means in plain words

Aprepitant and Tazemetostat can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Aprepitant belongs to Gastrointestinal Tract; Tazemetostat belongs to Miscellaneous.

Evidence level: Moderate

Why it happens

Aprepitant inhibits CYP3A4, decreasing tazemetostat metabolism.

What to do

Avoid if possible; otherwise reduce the tazemetostat dose per labeling and monitor for toxicity. Restore the prior dose after the inhibitor is stopped for about three half-lives.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Aprepitant and Tazemetostat, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Aprepitant with Tazemetostat?

MediHelp rates the interaction as major. Aprepitant and Tazemetostat can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Tazemetostat is a CYP3A4 substrate, and aprepitant can increase its concentrations. This may increase the risk of its adverse effects.

How serious is the interaction between Aprepitant and Tazemetostat?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid if possible; otherwise reduce the tazemetostat dose per labeling and monitor for toxicity. Restore the prior dose after the inhibitor is stopped for about three half-lives.

What other medicines interact with Aprepitant?

MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in